
Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

The approval was based on a phase 3 EDITION JUNIOR trial evaluating children and adolescents, aged 6 to 17 years, living with type 1 diabetes.
















In today’s fast-paced world, there are still family-owned pharmacies with a small-town vibe, including Lakes Apothecary.

The tool, which works by attaching a small sensor to the patient’s inhaler, collects data on medication use and sends medication reminders, progress reports, and disease insights to the patient’s smartphone or hub.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss value-based care and whether or not it poses challenge to data standardization in specialty pharmacy during the NASP Annual Meeting in Washington, DC.

The findings suggest that biologics can be used for those with elderly-onset rheumatoid arthritis (RA) as effectively as for those with young-onset RA.

Top news of the day from across the health care landscape.

Exercise improves psychological, behavioral, neurobiological, and overall health of patients.

Metformin hydrochloride extended-release tablets are indicated to for improving glycemic control in patients with type 2 diabetes mellitus, as an adjunct to diet and exercise.

The phase 3b/4 SPIRIT head-to-head study evaluated ixekizumab (Taltz) versus adalimumab (Humira) in psoriatic arthritis.

The FDA approved elexacaftor/tezacaftor/ivacaftor (Trikafta) earlier this month based on the results of a phase 3 clinical trial.

Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.

Managing elevated cholesterol is one of the the key elements to decreasing negative outcomes in atherosclerotic cardiovascular disease.